-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target

Benzinga·07/17/2026 12:34:51
Listen to the news
Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.